Forest Laboratories, Inc. Files Additional Lawsuit against First Time US Generics LLC for Infringement of SAVELLA® Patents

Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced that Forest and Royalty Pharma Collection Trust (“Royalty Pharma”) have jointly filed an additional lawsuit in the U.S. District Court for the District of Delaware against First Time US Generics LLC (“First Time”) for infringement of U.S. Patent No. 6,602,911 (“the ‘911 patent”), U.S. Patent No. 7,888,342 (“the ‘342 patent”), and U.S. Patent No. 7,994,220 (“the ‘220 patent), which relate to Forest’s SAVELLA® product. Forest licenses the ‘911 patent, the ‘342 patent, and the ‘220 patent from Royalty Pharma. The ‘911 patent expires in January 2023, the ‘342 patent expires in November 2021, and the ‘220 patent expires in September 2029.

Forest and Royalty Pharma received notification from First Time that it has filed an Abbreviated New Drug Application with Paragraph IV certifications seeking approval to market generic versions of SAVELLA before the expiration of the ‘911 patent, the ‘342 patent, and the ‘220 patent. This lawsuit was commenced before the expiration of forty-five days from the date of receipt of First Time’s notification letter.

About Forest Laboratories

Forest Laboratories' (NYSE:FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.

Forest Laboratories, Inc.Frank J. Murdolo, 1-212-224-6714Vice President - Investor Relationsmedia.relations@frx.com

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2024 to Aug 2024